Abstract
Deloitte Access Economics was commissioned by AstraZeneca Australia to estimate the economic cost of acute coronary syndrome (ACS) and to explore the extent of investment in secondary prevention of ACS.
| Original language | English |
|---|---|
| Place of Publication | Sydney |
| Publisher | Deloitte |
| Commissioning body | AstraZeneca Australia |
| Number of pages | 83 |
| Publication status | Published - 2011 |
| Externally published | Yes |